Background Glioma patients suffer from a wide range of symptoms which influence quality of
life negatively. The aim of this review is to give an overview of symptoms most prevalent in …

Background Treatment options for recurrent glioblastoma are scarce, with second-line
chemotherapy showing only modest activity against the tumour. Despite the absence of well …

Purpose To give an up-to-date overview of the potential clinical utility of 18 F-labelled choline
derivatives for tumour imaging with positron emission tomography. Methods A PubMed …

Background Effective treatments are needed to improve outcomes for high-grade glioma and
low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in …

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …

Although BRAF inhibitor monotherapy yields response rates >50% in BRAF V600 -mutant
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond. …

Introduction: Glioblastoma multiforme is the most common and aggressive primary brain
tumor. Valproate has been used as an anti-epileptic drug and mood stabilizer for decades. …

Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT) + temozolomide (TMZ). The purpose of the …

Purpose To assess the outcome of prostate cancer (PCa) patients diagnosed with
oligometastatic disease at recurrence and treated with stereotactic body radiotherapy (SBRT). …

Activated microglia are involved in the immune response of multiple sclerosis (MS). The
peripheral benzodiazepine receptor (PBR) is expressed on microglia and up‐regulated after …